

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

RANBAXY LABORATORIES LTD and RANBAXY INC.,

Petitioners

v.

ADAMAS PHARMACEUTICALS, INC.,

Patent Owner

Inter Partes Review No.: 2015-00410

U.S. Patent No. 8,362,085

Petitioners' Mandatory Notices – Updated Identification of Counsel
37 C.F.R. § 42.8

Petitioners Ranbaxy Laboratories Ltd. and Ranbaxy Inc. (“Petitioners”) hereby provide notice that it has updated counsel in this proceeding. Petitioners have added John W. Bateman as lead counsel, and Karen C. Shen as back-up counsel. Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioners’ updated mandatory notices are below, reflecting these amendments.

I. MANDATORY NOTICES (37 C.F.R. § 42.8)

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))

Ranbaxy Laboratories Limited and Ranbaxy Inc. are the real parties-in-interest for Petitioners.

Ranbaxy Inc. is a wholly owned subsidiary of Ranbaxy Holdings (U.K.) Ltd., which is a wholly owned subsidiary of Ranbaxy (Netherlands) B.V., which is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. Ranbaxy Laboratories Ltd. is a publicly held entity. Its shares are listed on the Stock Exchanges in India, *viz.* National Stock Exchange and The Stock Exchange, Mumbai. Its Global Depository Shares are listed on the Luxembourg Stock Exchange. Daiichi Sankyo Company, Ltd., a publicly traded entity on the Stock Exchanges in Japan, owns approximately 64% of the outstanding shares of Ranbaxy Laboratories Ltd.’s stock.

B. Related Matters (37 C.F.R. § 42.8(b)(2))

Petitioners are not aware of any reexamination certificates or pending prosecution concerning the ’085 patent. Petitioners are parties to a pending litigation

regarding infringement and invalidity of the '085 patent, namely *Forest Laboratories, Inc. et al v. Ranbaxy Inc. et. al*, Civ. Action No. 14-cv-686, currently pending in the District of Delaware. There are also pending litigations regarding infringement and invalidity of the '085 patent currently pending against additional parties in the District of Delaware, including Civ. Action Nos. 14-cv-121 , 14-cv-200, 14-cv-508, 14-cv-1058, and 14-cv-1271.

There are also two pending applications claiming benefit to the '085 patent, namely No. 14/081,643, filed on November 15, 2013, and No. 14/339,599, filed on July 24, 2014.

C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))

Lead Counsel	Back-up Counsel
John W. Bateman (Reg. No. 41,602) KENYON & KENYON LLP 1500 K Street, NW Washington, DC 20005 jbateman@kenyon.com Tel: 202.220.4216 Fax: 202.220.4201	Karen C. Shen (Reg. No. 60,412) KENYON & KENYON LLP One Broadway New York, NY 10004-1007 kshen@kenyon.com Tel: 212.908.6206 Fax: 212.425.5288

D. Service Information (37 C.F.R. § 42.8(b)(4))

Please direct all correspondence to lead counsel and back-up counsel at the contact information above. Petitioners consent to service by electronic mail at jbateman@kenyon.com and kshen@kenyon.com.

Dated: February 20, 2015

John W. Bateman

John W. Bateman
(Reg. No. 41,602)
KENYON & KENYON LLP
1500 K Street, NW
Washington, DC 20005
jbateman@kenyon.com
Tel: 202.220.4216
Fax: 202.220.4201


CERTIFICATE OF SERVICE

The undersigned hereby confirms that the foregoing *Petitioners' Mandatory Notices – Updated Identification of Counsel* was served on February 20, 2015 via e-mail upon the following counsel of record for the Patent Owner.

Peter J. Armenio, P.C.
QUINN EMMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

Evangeline L. Shih
QUINN EMMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

Dated: February 20, 2015



Hannah Rose Stein
KENYON & KENYON LLP
One Broadway
New York, NY 10004-1007
hstein@kenyon.com
Tel: 212.908.6398
Fax: 212.425.5288